The Food and Drug Administration (FDA) of the United States has recently approved Dupixent 300 mg produced by Sanofi for the purpose of treating the patients with the eosinophilic esophagitis (EoE) for the people above 12 years and older, which is weighing at least 40 kilograms.
With the help of this approval, the Dupixent has become the first and only medicine that is specifically indicating to treat the disease EoE in the United States. A regulatory filing for the EoE has been under the review by the European Medicines Agency (EMA) and the admissions to the regulatory authorities in the additional countries have been planned by the end of 2022.
Mary Jo Strobel, executive director of the American Partnership for Eosinophilic Disorders (APFED) said, they have now waited a very long time for an treatment option approved by US FDA for the esophagus that can possibly make it extremely challenging and uncomfortable for swallowing and eating.
He also said that, there had been no approved treatments specifically for the eosinophilic esophagitis that is resulting in most of the people needing to maintain a strict diet and also live in the constant fear of the food getting stuck in the throat of the patients.
The EoE disease has been a chronic inflammatory disease that is driven by the type 2 inflammation that is damaging the esophagus and also preventing it from working properly and for the patients of EoE, swallowing very small amounts of the food can be very painful and also worrisome choking experience.